Clinical phenotypes of castration-resistant prostate cancer

Clinical Advances in Hematology and Oncology

Volumn 11, Issue 11, 2013, Pages

  Zhang, Tian ^a   Armstrong, Andrew J ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; Castration resistant prostate cancer; Clinical phenotype; Genotype; Neuroendocrine prostate cancer; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; SYNAPTOPHYSIN; ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CHROMOSOME REARRANGEMENT; CIRCULATING TUMOR CELL; DISEASE CLASSIFICATION; GENOTYPE PHENOTYPE CORRELATION; HISTOLOGY; HUMAN; METASTASIS; PAIN; PHENOTYPE; PROGNOSIS; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC); GENETICS; MALE; METABOLISM; PATHOLOGY;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PHENOTYPE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84889600972     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Antonarakis ES, Armstrong AJ. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011;14(3):206-218.
3. Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2012;30(6):644-646.
4. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuro-endocrine prostate cancer and identifcation of new drug targets. Cancer Discov. 2011;1(6):487-495.
5. Tzelepi V, Zhang J, Lu J F, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012;18(3):666-677.
6. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol. 2011;29(27):3659-3668.
7. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239-243.
8. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell. 2008;14(2):111-122.
9. Aryee MJ, Liu W, Engelmann JC, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metas-tases. Sci Transl Med. 2013;5(169):169ra110. doi:10.1126/scitranslmed.3005211.
10. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33-39.
11. Gleason D F. Classifcation of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125-128.
12. Gleason D F, Mellinger GT. Prediction of prognosis for prostatic adeno-carcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.
13. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. Te 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29(9):1228-1242.
14. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisen-berger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13(21):6396-6403.
15. Halabi S, Small EJ, Kantof P W, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232-1237.
16. Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI. Prostate carcinoma with squamous diferentiation: an analysis of 33 cases. Am J Surg Pathol. 2004;28(5):651-657.
17. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med. 2007;357(26):2696-2705.
18. Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. 2012;15(3):283-288.
19. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006;30(6):705-712.
20. Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine diferentiation of prostate cancer. J Biol Chem. 2007;282(6):3571-3583.
21. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
22. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992;147(3 Pt 2):935-937.
23. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based che motherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621-3630.
24. ClinicalTrials.gov. A phase II trial of MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer. http://clinicaltrials.gov/ show/NCT01799278. Identifer: NCT01799278. Updated February 25, 2013. Accessed October 2, 2013.
25. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64(24):9209-9216.
26. Armstrong AJ, Tannock I F, de Wit R, George DJ, Eisenberger M, Halabi S. Te development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46(3):517-525.
27. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.
28. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specifc antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23(13):2918-2925.
29. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to frst bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117(10):2077-2085.
30. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001;91(1):66-73.
31. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11(11):1287-1296.
32. Datta K, Muders M, Zhang H, Tindall DJ. Mechanism of lymph node metastasis in prostate cancer. Future Oncol. 2010;6(5):823-836.
33. Touijer KA, Mazzola CR, Sjoberg DD, Scardino P T, Eastham JA. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. 2013. http:// dx.doi.org/10.1016/j.eururo.2013.03.053.
34. Bitting RL, Schaefer D, Somarelli JA, Garcia-Blanco MA, Armstrong AJ. Te role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev. In press.
35. Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metasta-ses target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121(4):1298-1312.
36. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010;116(6):1406-1418.
37. Armstrong AJ, Marengo MS, Oltean S, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mes-enchymal markers. Mol Cancer Res. 2011;9(8):997-1007.
38. Tanaka H, Kono E, Tran C P, et al. Monoclonal antibody targeting of N-cad-herin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010;16(12):1414-1420.
39. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22(3):373-388.
40. Saad F, Gleason DM, Murray R, et al; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
41. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822.
42. Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013;11(1):20-26.
43. Parker C, Nilsson S, Heinrich D, et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223.
44. Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. Te prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer [published online October 5, 2013]. Eur Urol. doi: 10.1016/j.eururo.2013.09.024.
45. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following frst-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16(1):203-211.
46. Loriot Y, Fizazi K, De Bono JS, Forer D, Hirmand M, Scher HI. Outcomes in patients with liver and/or lung metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide: results from the phase 3 AFFIRM trial [ASCO abstract 5065]. J Clin Oncol. 2013;31(15S).
47. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specifc antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25(25):3965-3970.
48. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI; TAX-327 investigators. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specifc antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14(9):2763-2767.
49. Nelson J, Bagnato A, Battistini B, Nisen P. Te endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3(2):110-116.
50. Berthold DR, Pond G, De Wit R, Eisenberger MA, Tannock I F. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study [ASCO abstract 4516]. J Clin Oncol. 2006;24(18S).
51. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008;26(15):2544-2549.
52. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal- related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210-1217.
53. Berry WR, Laszlo J, Cox E, Walker A, Paulson D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer. 1979;44(2):763-775.
54. Rana A, Chisholm GD, Rashwan HM, Salim A, Merrick MV, Elton RA. Symptomatology of metastatic prostate cancer: prognostic significance. Br J Urol. 1994;73(6):683-686.
55. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20(19):3972-3982.
56. Johansson JE, Wersäll P, Brandberg Y, Andersson SO, Nordström L; EPO-Study Group. Efcacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study. Scand J Urol Nephrol. 2001;35(4):288-294.
57. Winquist E, Julian JA, Moore MJ, et al. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia. J Clin Oncol. 2009;27(4):644-646.
58. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.
59. Scher HI, Fizazi K, Saad F, et al; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
60. Ryan CJ, Smith MR, de Bono JS, et al; COU-AA-302 Investigators. Abi-raterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148.
61. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61(3):549-559.
62. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695-3704.
63. Kantof PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
64. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534-1540.
65. Huggins C, Hodges CV. Studies on prostatic cancer. I. Te efect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;167(2 pt 2):948-951, discussion 952.
66. Sonpavde G, Pond GR, Berry WR, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration- resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30(5):607-613.
67. Saylor PJ, Armstrong AJ, Fizazi K, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013;63(2):309-320.
68. Sartor AO, Amariglio R, Wilhelm S, et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. [ASCO abstract 5080]. J Clin Oncol. 2013;31(15S).
69. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival beneft in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30(27):3402-3407.
70. Scher HI, Heller G, Molina A, et al. Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mCRPC). Paper presented at: European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, the Netherlands. Abstract 2851.
71. Spiess PE, Pettaway CA, Vakar-Lopez F, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007;110(8):1729-1737.
72. Taplin ME, George DJ, Halabi S, et al. Prognostic signifcance of plasma chro-mogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005;66(2):386-391.
73. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival beneft from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302-6309.
74. Chan F, Goodman O, Fink L, Vogelzang NJ, Pomerantz D, Khoury JD. Dramatically elevated circulating tumor cell numbers in a patient with small cell neuro-endocrine carcinoma of the prostate. Arch Pathol Lab Med. 2010;134(1):120-123.
75. Rao CG, Chianese D, Doyle G V, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 2005;27(1):49-57.
76. Joosse SA, Hannemann J, Spötter J, et al. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res. 2012;18(4):993-1003.
77. Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009;101(1):61-66.
78. Bitting RL, Healy P, Halabi S, George DJ, Ko JH, Armstrong AJ. Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) [ASCO abstract 5031]. J Clin Oncol. 2013;31(15S).
79. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13(23):7053-7058.
80. Berger M F, Lawrence MS, Demichelis F, et al. Te genomic complexity of primary human prostate cancer. Nature. 2011;470(7333):214-220.
81. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-648.
82. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associ-ated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012;181(2):401-412.
83. Magbanua MJ, Sosa EV, Scott JH, et al. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer. 2012;12(78).
84. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
85. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153(3):666-677.
86. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer. 2007;97(12):1690-1695.
87. Saramäki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visa-korpi T. TMPRSS2:ERG fusion identifes a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008;14(11):3395-3400.
88. Attard G, Clark J, Ambroisine L, et al; Transatlantic Prostate Group. Duplication of the fusion of TMPRSS2 to ERG sequences identifes fatal human prostate cancer. Oncogene. 2008;27(3):253-263.
89. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15(15):4792-4798.
90. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifes recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685-689.